Clinical Efficacy and Safety of Yellow Oil Formulations 3 and 4 versus Indomethacin Solution in Patients with Symptomatic Osteoarthritis of the Knee: A Randomized Controlled Trial

Table 1

Characteristics of study participants.

	YOF3 (n = 34)	YOF4 (n = 34)	INDO (n = 34)
Gender (female: male)	32 : 2	30 : 4	31 : 3
Age (years)^1	62.29 ± 7.89	62.18 ± 6.77	60.76 ± 7.03
BMI (kg/m^2)^1	25.56 ± 3.73	25.86 ± 3.91	27.51 ± 4.81
Localization of OA (right knee: left knee: both knees)	5 : 5: 24	1 : 6: 27	2 : 5: 27
Kellgren and Lawrence X-ray grade (Grade 2: Grade 3: Grade 4)	20 : 23: 15	22 : 20: 19	29 : 15: 17
VAS pain^1	53.65 ± 8.03	52.71 ± 9.45	49.24 ± 9.61
VAS stiffness^1	45.79 ± 14.11	50.53 ± 15.40	47.76 ± 15.02
KOOS^1
Pain	53.59 ± 13.62	57.00 ± 13.29	53.68 ± 15.54
Other knee symptoms	58.91 ± 13.56	63.21 ± 15.57	58.38 ± 14.05
Activities of daily living	54.12 ± 13.88	55.26 ± 15.84	55.76 ± 17.05
Sport and recreation function	30.00 ± 16.24	25.59 ± 19.84	27.94 ± 19.70
Knee-related quality of life	33.29 ± 16.81	32.71 ± 13.66	32.47 ± 15.80

¹Data shown as mean ± SD.